<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">28577493</PMID>
      <DateCompleted>
        <Year>2018</Year>
        <Month>04</Month>
        <Day>03</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1950-6007</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>92</Volume>
            <PubDate>
              <Year>2017</Year>
              <Month>Aug</Month>
            </PubDate>
          </JournalIssue>
          <Title>Biomedicine &amp; pharmacotherapy = Biomedecine &amp; pharmacotherapie</Title>
          <ISOAbbreviation>Biomed Pharmacother</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Inhibition of PI3K/AKt/mTOR signaling pathway protects against d-galactosamine/lipopolysaccharide-induced acute liver failure by chaperone-mediated autophagy in rats.</ArticleTitle>
        <Pagination>
          <StartPage>544</StartPage>
          <EndPage>553</EndPage>
          <MedlinePgn>544-553</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.biopha.2017.05.037</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0753-3322(17)31103-4</ELocationID>
        <Abstract>
          <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This study aims to investigate the effects of PI3K/AKt/mTOR signaling pathway on the proliferation and apoptosis in acute liver failure (ALF) by chaperone mediated autophagy (CMA).</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">The hepatocytes extracted from both normal rats and rats with ALF were assigned to control, acute injury, P13K agonist, and P13K inhibitor groups. Quantitative real-time polymerase chain reaction (qRT-PCR) and western blotting were used as part of this investigation to detect the expression of PI3K/AKt/mTOR signaling pathway related-proteins (PI3K, AKt, mTOR), apoptosis related-proteins (Fas, Bax, Bcl-2), chaperone-mediated autophagy (CMA) marker proteins (LAMP-2A, HSC 70), p-PI3K, p-AKt, p-4E-BPI, and p-S6K. An MTT assay was used for analysis of cell proliferation after transfection. Flow cytometry is performed to detect the cell apoptosis.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">In comparison to the normal group, the model group showed enhanced positive rate of PI3K, AKt, mTOR, increased expression levels of PI3K, AKt, mTOR, Fas, Bax, p-PI3K, p-AKt, p-4E-BPI and p-S6K, reduced expression levels of Bcl-2, LAMP-2A and HSC 70. The results in vitro experiment: compared with the acute injury group, the PI3K agonist group showed elevated expression levels of PI3K, AKt, mTOR, Fas, Bax, p-PI3K, p-AKt, p-4E-BPI and p-S6K, decreased expression levels of Bcl-2, LAMP-2A and HSC 70, inhibited cell proliferation, more arrested cells in G1 stage, and promoted cell apoptosis. Opposing this, the P13K inhibitor group exhibited an opposite trend.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In conclusion, inhibition of the PI3K/AKt/mTOR signaling pathway plays a protective role in ALF by promoting CMA expression, which could arrest cell proliferation and promote cell apoptosis.</AbstractText>
          <CopyrightInformation>Copyright Â© 2017 Elsevier Masson SAS. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Yin</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Intensive Care Unit, Emergency Medical Research Institute, Tianjin First Center Hospital, Tianjin 300192, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lu</LastName>
            <ForeName>Ling</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Intensive Care Unit, Emergency Medical Research Institute, Tianjin First Center Hospital, Tianjin 300192, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Luo</LastName>
            <ForeName>Ning</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Intensive Care Unit, Emergency Medical Research Institute, Tianjin First Center Hospital, Tianjin 300192, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Yong-Qiang</ForeName>
            <Initials>YQ</Initials>
            <AffiliationInfo>
              <Affiliation>Intensive Care Unit, Emergency Medical Research Institute, Tianjin First Center Hospital, Tianjin 300192, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gao</LastName>
            <ForeName>Hong-Mei</ForeName>
            <Initials>HM</Initials>
            <AffiliationInfo>
              <Affiliation>Intensive Care Unit, Emergency Medical Research Institute, Tianjin First Center Hospital, Tianjin 300192, PR China. Electronic address: Hongmei0306@163.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>France</Country>
        <MedlineTA>Biomed Pharmacother</MedlineTA>
        <NlmUniqueID>8213295</NlmUniqueID>
        <ISSNLinking>0753-3322</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008070">Lipopolysaccharides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018832">Molecular Chaperones</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000081082">Phosphoinositide-3 Kinase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>7535-00-4</RegistryNumber>
          <NameOfSubstance UI="D005688">Galactosamine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.1.1</RegistryNumber>
          <NameOfSubstance UI="C546845">mTOR protein, rat</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005688" MajorTopicYN="N">Galactosamine</DescriptorName>
          <QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008070" MajorTopicYN="N">Lipopolysaccharides</DescriptorName>
          <QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017114" MajorTopicYN="N">Liver Failure, Acute</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018832" MajorTopicYN="N">Molecular Chaperones</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000081082" MajorTopicYN="N">Phosphoinositide-3 Kinase Inhibitors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Acute liver failure</Keyword>
        <Keyword MajorTopicYN="N">Chaperone-mediated autophagy</Keyword>
        <Keyword MajorTopicYN="N">PI3K/AKt/mTOR signaling pathway</Keyword>
        <Keyword MajorTopicYN="N">d-Galactosamine/lipopolysaccharide</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2017</Year>
          <Month>3</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2017</Year>
          <Month>5</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2017</Year>
          <Month>5</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2017</Year>
          <Month>6</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2018</Year>
          <Month>4</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2017</Year>
          <Month>6</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">28577493</ArticleId>
        <ArticleId IdType="doi">10.1016/j.biopha.2017.05.037</ArticleId>
        <ArticleId IdType="pii">S0753-3322(17)31103-4</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
